Gongwin Biopharm Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Gongwin Biopharm Holdings has a total shareholder equity of NT$3.3B and total debt of NT$241.6M, which brings its debt-to-equity ratio to 7.3%. Its total assets and total liabilities are NT$3.7B and NT$385.6M respectively.
Key information
7.3%
Debt to equity ratio
NT$241.55m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$2.88b |
| Equity | NT$3.31b |
| Total liabilities | NT$385.58m |
| Total assets | NT$3.69b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6617's short term assets (NT$3.1B) exceed its short term liabilities (NT$298.7M).
Long Term Liabilities: 6617's short term assets (NT$3.1B) exceed its long term liabilities (NT$86.9M).
Debt to Equity History and Analysis
Debt Level: 6617 has more cash than its total debt.
Reducing Debt: 6617's debt to equity ratio has reduced from 8.5% to 7.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6617 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6617 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 7.9% each year